ES2279153T3 - Formulacion de depositio inyectable formada por cristales de iloperidona. - Google Patents

Formulacion de depositio inyectable formada por cristales de iloperidona. Download PDF

Info

Publication number
ES2279153T3
ES2279153T3 ES03756455T ES03756455T ES2279153T3 ES 2279153 T3 ES2279153 T3 ES 2279153T3 ES 03756455 T ES03756455 T ES 03756455T ES 03756455 T ES03756455 T ES 03756455T ES 2279153 T3 ES2279153 T3 ES 2279153T3
Authority
ES
Spain
Prior art keywords
crystals
formulation according
deposit
iloperidone
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03756455T
Other languages
English (en)
Spanish (es)
Inventor
Dierk Wieckhusen
Alexandra Glausch
Markus Ahlheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9940486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2279153(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2279153T3 publication Critical patent/ES2279153T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES03756455T 2002-07-15 2003-07-14 Formulacion de depositio inyectable formada por cristales de iloperidona. Expired - Lifetime ES2279153T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0216416 2002-07-15
GBGB0216416.8A GB0216416D0 (en) 2002-07-15 2002-07-15 Organic compounds

Publications (1)

Publication Number Publication Date
ES2279153T3 true ES2279153T3 (es) 2007-08-16

Family

ID=9940486

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03756455T Expired - Lifetime ES2279153T3 (es) 2002-07-15 2003-07-14 Formulacion de depositio inyectable formada por cristales de iloperidona.

Country Status (15)

Country Link
US (5) US20050250813A1 (enExample)
EP (1) EP1523335B1 (enExample)
JP (2) JP5392961B2 (enExample)
AT (1) ATE348635T1 (enExample)
AU (1) AU2003281154B2 (enExample)
CA (1) CA2492467C (enExample)
CY (1) CY1106305T1 (enExample)
DE (1) DE60310564T2 (enExample)
DK (1) DK1523335T3 (enExample)
ES (1) ES2279153T3 (enExample)
GB (1) GB0216416D0 (enExample)
NZ (1) NZ537598A (enExample)
PT (1) PT1523335E (enExample)
WO (1) WO2004006886A2 (enExample)
ZA (1) ZA200410323B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0213564B8 (pt) 2001-10-30 2021-05-25 Novartis Ag formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
WO2006039663A2 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals, Inc Methods for the administration of iloperidone
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
SI2170279T1 (en) 2007-07-31 2018-04-30 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
CA2698534C (en) 2007-09-10 2018-10-09 Vanda Pharmaceuticals, Inc. Prediction of qt prolongation based on snp genotype
EP2222301B1 (en) 2007-12-13 2014-10-08 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
WO2009076664A1 (en) 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
WO2010031497A1 (en) * 2008-09-19 2010-03-25 Miklos Vertessy New process for the preparation of iloperidone
CN101822673B (zh) * 2009-03-04 2013-09-18 北京德众万全药物技术开发有限公司 一种含有伊潘立酮的固体药物组合物
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
WO2011032404A1 (zh) 2009-09-19 2011-03-24 浙江华海药业股份有限公司 伊潘立酮的一种制备方法及结晶方法
CN102030744B (zh) * 2009-09-30 2013-04-17 天津药物研究院 伊潘立酮晶体、其制备方法及药物组合物
WO2011055188A1 (en) * 2009-11-05 2011-05-12 Orchid Chemicals And Pharmaceuticals Limited An improved process for the preparation of iloperidone
BR112012015084A2 (pt) * 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
CN102108081A (zh) * 2009-12-25 2011-06-29 重庆医药工业研究院有限责任公司 伊潘立酮的新晶型及其制备方法
SG182285A1 (en) 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
CN101822674B (zh) * 2010-05-27 2015-03-11 北京德众万全医药科技有限公司 一种伊潘立酮药物组合物及其制备方法
EP2629775A4 (en) * 2010-10-18 2014-06-11 Dainippon Sumitomo Pharma Co INJECTABLE FORMULATION WITH DELAYED RELEASE
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
WO2012090138A1 (en) 2010-12-27 2012-07-05 Ranbaxy Laboratories Limited Processes for the preparation of iloperidone
CN102680636A (zh) * 2011-03-11 2012-09-19 天津药物研究院 一种伊潘立酮原料药及其中间体的质量控制方法
KR102593047B1 (ko) 2012-01-26 2023-10-24 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CN102633786B (zh) * 2012-04-18 2013-11-27 吉林三善恩科技开发有限公司 一种伊潘立酮药物共晶及其制备方法
CN102659771B (zh) * 2012-04-18 2013-11-27 吉林三善恩科技开发有限公司 一种伊潘立酮药物共晶及其制备方法
JP5959083B2 (ja) 2012-05-18 2016-08-02 ヴァンダ ファーマシューティカルズ インコーポレイテッド （１Ｒ−ｔｒａｎｓ）−Ｎ−［［２−（２，３−ジヒドロ−４−ベンゾフラニル）シクロプロピル］メチル］プロパンアミドの代謝物
WO2014100292A1 (en) 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
CN103599074A (zh) * 2013-11-26 2014-02-26 重庆医药工业研究院有限责任公司 一种伊潘立酮缓释微球及其制备方法
ES2870498T3 (es) 2015-02-17 2021-10-27 Vanda Pharmaceuticals Inc Iloperidona para el tratamiento de esquizofrenia
US11071728B2 (en) 2015-12-11 2021-07-27 Vanda Pharmaceuticals Inc. Treatment of schizophrenia
CN106831741B (zh) * 2016-12-28 2019-08-23 北京医药集团有限责任公司 一种伊潘立酮超细粉体的制备方法
US10935106B2 (en) * 2018-06-14 2021-03-02 Serapid, Inc. Block chain with monolithic links
BR112021009265A2 (pt) * 2018-12-04 2021-08-10 Vanda Pharmaceuticals Inc. métodos para preparar e administrar uma formulação de depósito injetável de iloperidona cristalina, e, formulação de depósito injetável de iloperidona cristalina
US20200171018A1 (en) * 2018-12-04 2020-06-04 Vanda Pharmaceuticals Inc. Depot administration of iloperidone
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
AU2023408198A1 (en) 2022-12-19 2025-05-29 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB216416A (en) 1923-09-06 1924-05-29 James Baker And Sons Ltd Improvements in boots and shoes
IT1093097B (it) * 1976-10-28 1985-07-19 Hoechst France Acidi n-carbetossi(alfa-amminofenilacetici)otticamente attivi relativo procedimento di produzione e loro impiego per la produzione di acidi alfa-ammino-fenilacetici otticamente attivi corrispondenti
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
DE3345355A1 (de) * 1983-12-15 1985-06-27 Hoechst Ag, 6230 Frankfurt Verfahren zur racematspaltung bicyclischer imino-(alpha)-carbonsaeureester
DE3511587A1 (de) * 1985-03-27 1986-10-02 Schering AG, Berlin und Bergkamen, 1000 Berlin Glykoester des estradiols und estriols
US4886370A (en) 1987-08-25 1989-12-12 Nkk Corporation Method for detecting a state of substance existing in pipe
DE69021645T2 (de) * 1989-05-19 1996-02-22 Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J. N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
ES2098358T3 (es) * 1990-06-04 1997-05-01 Schering Corp Metodo para preparar cristales de interferon alfa-2.
CA2095499A1 (en) * 1992-05-08 1993-11-09 Petrus J. M. Van Den Oetelaar Depot preparation
DE69327542T2 (de) * 1992-11-17 2000-07-06 Yoshitomi Pharmaceutical Industries, Ltd. Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US5902882A (en) * 1996-04-17 1999-05-11 Hoffmann-La Roche Inc. Assymetric synthesis of azepines
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
WO1998054186A1 (en) * 1997-05-26 1998-12-03 Akzo Nobel N.V. Salts of aromatic sulphonic acids
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE19816070A1 (de) 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
WO2000023057A2 (en) 1998-10-16 2000-04-27 Janssen Pharmaceutica N.V. Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition
US6509310B1 (en) 2000-06-01 2003-01-21 Huish Detergents, Inc. Compositions containing α-sulfofatty acid esters and method of making the same
JP2003535106A (ja) 2000-06-02 2003-11-25 ノボ ノルディスク アクティーゼルスカブ グルコース検知性インスリン誘導体からの、インスリンのグルコース依存性放出
JP2005504783A (ja) * 2001-08-31 2005-02-17 ノバルティス アクチエンゲゼルシャフト イロペリドン代謝産物の光学異性体
BRPI0213564B8 (pt) * 2001-10-30 2021-05-25 Novartis Ag formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU2003281154B2 (en) 2006-10-12
US8293765B2 (en) 2012-10-23
GB0216416D0 (en) 2002-08-21
WO2004006886A3 (en) 2004-02-19
DE60310564T2 (de) 2007-10-04
NZ537598A (en) 2006-07-28
JP5392961B2 (ja) 2014-01-22
CY1106305T1 (el) 2011-10-12
PT1523335E (pt) 2007-02-28
DE60310564D1 (de) 2007-02-01
ZA200410323B (en) 2006-06-28
CA2492467A1 (en) 2004-01-22
CA2492467C (en) 2010-03-16
US8614232B2 (en) 2013-12-24
AU2003281154A1 (en) 2004-02-02
US20110212141A1 (en) 2011-09-01
WO2004006886A2 (en) 2004-01-22
US20120156264A1 (en) 2012-06-21
ATE348635T1 (de) 2007-01-15
JP5670698B2 (ja) 2015-02-18
JP2011016849A (ja) 2011-01-27
EP1523335B1 (en) 2006-12-20
JP2005533093A (ja) 2005-11-04
EP1523335A2 (en) 2005-04-20
US8227488B2 (en) 2012-07-24
US20050250813A1 (en) 2005-11-10
HK1076029A1 (en) 2006-01-06
US20090099232A1 (en) 2009-04-16
US20130012542A1 (en) 2013-01-10
DK1523335T3 (da) 2007-01-29

Similar Documents

Publication Publication Date Title
ES2279153T3 (es) Formulacion de depositio inyectable formada por cristales de iloperidona.
ES2315721T3 (es) Formulacion de aripiprazol inyectable esteril de liberacion controlada y procedimiento.
US20250241909A1 (en) Injectable formulation
KR101748890B1 (ko) 세프티오퍼 및 케토프로펜 또는 세프티오퍼 및 벤질 알코올을 포함하는 제형
ES2884825T3 (es) Dispositivo médico que contiene una composición de torta que comprende aripiprazol como principio activo y composición de torta que comprende aripiprazol como principio activo
EP4153133B1 (en) Injectable pharmaceutical compositions and uses thereof
ES2324009B1 (es) Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP6182262B2 (ja) 抗がん剤を含む安定な水溶性医薬組成物
US20240165107A1 (en) Long Acting Injectable Compositions of Cariprazine or its Pharmaceutically Acceptable Salts
JP2014516025A (ja) アリピプラゾール凍結乾燥製剤
EP3331516B1 (en) Hyperbaric injection solution of ropivacaine hydrochloride and process for preparation thereof
KR100983208B1 (ko) 티오트로퓸 염을 함유하는 용액의 흡입성 제형
HK1076029B (en) Injectable depot formulation comprising crystals of iloperidone
CN1832725A (zh) 含有三嗪的生物活性组合物